---
title: Prevalence of Osteoporosis in Sickle Cell Disease
nct_id: NCT04299594
overall_status: COMPLETED
sponsor: Hospices Civils de Lyon
study_type: OBSERVATIONAL
primary_condition: Sickle Cell Disease
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04299594.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04299594"
ct_last_update_post_date: 2023-02-09
last_seen_at: "2026-05-12T07:07:19.960Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Prevalence of Osteoporosis in Sickle Cell Disease

**NCT ID:** [NCT04299594](https://clinicaltrials.gov/study/NCT04299594)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 142
- **Lead Sponsor:** Hospices Civils de Lyon
- **Conditions:** Sickle Cell Disease
- **Start Date:** 2020-06-18
- **Completion Date:** 2021-12-18
- **CT.gov Last Update:** 2023-02-09

## Brief Summary

Sickle cell disease is the most common single-gene disease in the world. Its prevalence is increasing in France, with patients' life expectancy increasing into developed countries. It mainly affects populations originating from sub-Saharan Africa. Among the chronic bone complications associated with sickle cell disease, osteoporosis has previously been highlighted but remains a poorly known complication in this very particular context. A dedicated evaluation of osteoporosis and associated risk factors in sickle cell disease patients living in France may enable better bone management of these patients in the future, as this problem, specific to their disease, is likely to become more frequent as their life expectancy increases.

This is a prospective interventional and monocentric study whose objective is to describe the prevalence of osteoporosis in black patients with sickle cell disease in France

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 40 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Black-skinned men and women
* Aged 20 to 40 years old
* Sickle cell patients
* Non-opposition to participate in the study

Exclusion Criteria:

* Refusal to participate in the study
* Hemoglobinopathy other than sickle cell disease
* Severe or End Stage Renal Failure
* Long-term corticosteroid therapy (\>3 months)
* History of solid cancer or malignant haemopathy
* History of organ transplantation
* Pregnant or breastfeeding woman
* Psychiatric pathology seriously impeding understanding
* Difficulty understanding oral French
```

## Arms

- **sickle cell disease patients** — 150 black patients with sickle cell disease living in France, 20 to 40 years old will be included in this study

## Interventions

- **Questionnaire** (OTHER) — For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.

## Primary Outcomes

- **Bone mineral density** _(time frame: Day 1)_ — Bone mineral density is measured by systematic bone densitometry at 3 sites: lumbar spine, femoral neck and total hip. These data will be collected in the patient's medical record

## Locations (1)

- Hôpital Edouard Herriot, Lyon, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hôpital edouard herriot|lyon||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04299594.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04299594*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*